Colorectal cancer (CRC) is one the greatest contributors to cancer related mortality.
Although 5 year survival rate for patients at the early stage of CRC (stages I and II) is above …

Nearly 350 IgG-based therapeutics are approved for clinical use or are under development
for many diseases lacking adequate treatment options. These include molecularly …

Implanted biomaterials often fail because they elicit a foreign body response (FBR) and
concomitant fibrotic encapsulation. To design clinically relevant interference approaches, it …

Monoclonal antibodies (mAbs) are one of the most important classes of therapeutic proteins,
which are used to treat a wide number of diseases (eg, oncology, inflammation and …

Angiogenesis is a crucial process for tissue development, repair, and tumor survival.
Vascular endothelial growth factor (VEGF) is a key driver secreted by cancer cells …

KSI-301 is a new intravitreal anti-vascular endothelial growth factor (VEGF) antibody
biopolymer conjugate under investigation for the treatment of age-related macular …

PURPOSE: To describe the pharmacokinetics, preclinical studies, and clinical trials of the
newly approved anti–vascular endothelial growth factor (VEGF) drug aflibercept (Eylea …

Treatment strategies for metastatic colorectal cancer (mCRC) patients have undergone
dramatic changes in the past decade and despite improved patient outcomes, there still exist …

Fc-fusion proteins are composed of Fc region of IgG antibody (Hinge-CH2-CH3) and a
desired linked protein. Fc region of Fc-fusion proteins can bind to neonatal Fc receptor …

Modulation of the interaction between the immune system and the tumor microenvironment
has long been a target of cancer research, including colorectal cancer (CRC). Approaches …